trial of octreotide in recurrent variceal bleeding

FREE subscriptions for doctors and students... click here
You have 3 more open access pages.

32 patients with biopsy-proven hepatic cirrhosis and a first variceal bleed were randomised to sclerotherapy alone or sclerotherapy plus six months of octreotide therapy.

The patients and clinicians were not blinded.

The main outcomes reported were:

  • frequency of rebleeding:
    • during the 6 months of the trial the number of patients who rebled was:
      • 1/16 in the combined octreotide/sclerotherapy group
      • 7/16 in the sclerotherapy alone group
      • p=0.037

  • mortality:
    • during the 6 months the mortality rate was:
      • 0/16 in the combined octreotide/sclerotherapy group
      • 5/16 in the sclerotherapy alone group
      • p<0.02

  • change in portal pressure:
    • during the 6 months the change in portal pressure was:
      • -6.0 mmHg in the combine treatment group
      • +1.5 mmHg in the sclerotherapy alone group

Reference:

  • Jenkins, SA. et al. (1997). Randomised trial of octreotide for long term management of cirrhosis after variceal haemorrhage. BMJ, 315, 1138-41.

Last reviewed 01/2018